NC DEPARTMENT OF HEALTH AND HUMAN SERVICES

Statewide Standing Order for COVID-19 Diagnostic Testing for All Persons
Updated: December 14, 2020

This standing order authorizes individuals (hereinafter, "patient") to obtain a SARS-CoV-2 diagnostic test at a testing site in accordance with the conditions of this order and any North Carolina licensed healthcare provider, in accordance with the conditions of their licensure (including a physician, advanced-practice provider [nurse practitioner, certified nurse midwife, physician assistant], registered nurse, licensed practical nurse, licensed pharmacist, licensed dentist), and trained unlicensed personnel working under the direct supervision of a physician, advanced-practice provider, registered nurse, licensed pharmacist, or licensed dentist, in accordance with the conditions of their licensure, at a healthcare facility or medically-supervised COVID-19 testing site in the state (collectively, "testers") to collect and submit for laboratory analysis a COVID-19 diagnostic test for any individual (hereinafter, "patient") in accordance with the conditions of this order and authorizes the healthcare facility, pharmacy, or testing site that submitted the specimen for COVID-19 diagnostic testing under this order to receive the results of the test directly from the testing laboratory. Nothing in this standing order is intended to authorize a healthcare provider to practice outside their legally defined scope of practice.

COVID-19 Testing	
Condition or Situation	Patient presents requesting and consents to COVID-19 diagnostic testing.
Assessment Criteria	
Assessment Criteria	Patients shall be tested for COVID-19 based on the conditions of this order.
Plan of Care	
Actions	**1. Patient Education and Data Collection** a. Prior to collecting the specimen from the patient, the testing site shall provide anticipatory guidance regarding testing to the patient, which at minimum shall include: i. Where, how, and when to obtain the test result; ii. Information on control measures English|Spanish to follow while waiting for the test result and to follow if the test result is positive, based on Centers for Disease Control and Prevention (CDC) guidance; iii. Information on what to expect from the Contact Tracer who will be in touch following a positive test result; iv. Information on what to do and how to access medical care if the patient has or develops symptoms and how to link to a medical home; and v. Information on resources, such as access to shelter or food, if needed to adhere to control measures. b. Prior to collecting the specimen, the testing site must collect: i. Data required to be reported in accordance with 10A NCAC 41A .0107. For more information on reporting, see this guidance. ii. Household and close contact names to facilitate contact tracing. The patient has the option to refuse to provide this information

	during the testing process but will be required to provide information to a contact tracer if the result is positive. iii. The name and contact information of the patient's primary care provider, if available. **2. Specimen Collection, Testing, and Test Results** a. Consent must be obtained from the patient or the patient's legally authorized representative. If the patient is a minor, consent must be obtained from a parent or guardian or from the minor in accordance with G.S. 90-21.5. b. Testing sites shall collect a specimen for a COVID-19 diagnostic test approved by the US Food and Drug Administration (FDA) or authorized by the FDA through an Emergency Use Authorization (EUA). c. See *Contraindications for Use of this Order* section of this standing order. d. Specimen collection must be done as indicated by the test modality and samples stored and transported within the recommended ranges to achieve the highest sensitivity and specificity of results. e. Before collecting the specimen, don appropriate personal protective equipment (PPE). The type of PPE should be based on the type of test collection procedure and the testing location and include strategies to minimize transmission. f. Follow specimen collection, specimen storage, and testing methodologies required by the manufacturer and/or laboratory partner. g. If submitted to a laboratory, the testing sites shall direct the laboratory to return the test result to the testing site.
Follow-up	**Follow up and Contact Tracing** 1. The test result must be reported to the patient by a trained representative of the testing site or made available by the testing site as soon as possible, but no more than 24 hours after receiving result. The testing site shall also provide the test result to the patient's primary care provider, if available. 2. All positive and negative tests must be reported pursuant to GS 130A, Article 6, 10A NCAC 41A .0101, and 10A NCAC 41A .0107. For more information on reporting, see this guidance. 3. If the test result is positive, inform the patient of the control measures English|Spanish that should be implemented based on Centers for Disease Control and Prevention (CDC) guidance. Explain the subsequent contact tracing process, reinforce the confidentiality and safety of this process, and encourage the patient to follow up with contract tracers in an expeditious manner. Provide any information collected regarding household and close contact names to the local health department to facilitate contact tracing.
Contraindications for Use of this Order	There are no specific contraindications for collecting specimens. However, if the patient has had recent nasal trauma or surgery, has a markedly deviated nasal septum, or has a history of chronically blocked nasal passages or severe coagulopathy which create difficulty in obtaining a nasopharyngeal specimen, a

	trained licensed medical professional should be consulted to discuss alternative test collection procedures. https://www.cdc.gov/coronavirus/2019-ncov/lab/guidelines-clinical-specimens.html https://www.nejm.org/doi/full/10.1056/NEJMvcm2010260
Criteria or Circumstances for Notifying Medical Provider	Notify the physician or advanced practice provider (nurse practitioner, certified nurse-midwife, or physician assistant) from the organization providing clinical supervision of the testing site if questions or problems arise.

Approved by: ___ CT Tilson _____ Date approved: 12-14-20

Elizabeth Cuervo Tilson, MD, MPH

NPI: 1760540421

Effective Date: 12-14-20

Expiration Date: This standing order shall remain in force and effect for the duration of the state of emergency declared under Executive Order 116 unless otherwise modified, rescinded, or replaced.

Associated Guidelines:
CDC guidelines at:
https://www.cdc.gov/coronavirus/2019-nCoV/lab/guidelines-clinical-specimens.html

Legal Authority: G.S. 130A-3, GS 130A-5, Executive Order No. 147